What is astroblastoma, MN1-altered?
Astroblastoma is a rare brain tumour that usually grows in the cerebral hemispheres, the large upper parts of the brain. It most often affects children, teenagers and young women. The tumour was first described almost a century ago, but for decades doctors disagreed about what kind of cell it came from and how it should be classified (Lehman, 2023).
Under the microscope, astroblastoma cells are arranged around blood vessels like the spokes of a wheel, forming so-called astroblastic pseudorosettes. Many tumours with this appearance, especially in young people, carry a rearrangement of a gene called MN1 on chromosome 22. The MN1 gene is often joined to a partner gene on the X chromosome, most commonly BEND2, creating an MN1::BEND2 fusion.
The World Health Organization (WHO) classification of brain tumours now defines astroblastoma by this genetic change, using the name “astroblastoma, MN1-altered”. Tumours that look like astroblastoma but lack an MN1 change, particularly in adults, often turn out to be other tumour types when tested more fully (Boisseau et al., 2019).
Most MN1-altered astroblastomas are well defined and can often be removed completely by surgery. Many patients do well after surgery, but some tumours come back, so long-term follow-up with MRI scans is important. Radiotherapy and chemotherapy are used for tumours that recur or cannot be fully removed.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Circumscribed glial tumour defined by MN1 alteration |
| Where it grows | Cerebral hemispheres, usually near the brain surface |
| Who is affected | Mainly children, teenagers and young adults; strong female predominance |
| Genetic hallmark | MN1 rearrangement, often MN1::BEND2 fusion |
| Main symptoms | Headaches, seizures, nausea, weakness |
| Scan appearance | Well-defined, mixed cystic and solid enhancing mass with a “bubbly” look |
| Main treatment | Surgical removal; radiotherapy for some |
| WHO grade | Not yet formally assigned |
| Outlook | Often good after complete removal; recurrence possible |
2. Types
Tumours with astroblastoma-like appearance
| Tumour | Key genetic feature | Usual patient | Behaviour |
|---|---|---|---|
| Astroblastoma, MN1-altered | MN1 rearrangement (often with BEND2) | Girls and young women | Often favourable after removal |
| Pleomorphic xanthoastrocytoma-like tumours | BRAF mutation | Adults and young people | Often favourable |
| High-grade glioma-like tumours | Alterations typical of glioblastoma or diffuse midline glioma | Adults | Aggressive |
| Ependymoma | Various fusions | Children and adults | Variable |
In a study of 15 adolescents and adults with tumours that had been diagnosed as astroblastoma, only one had an MN1 fusion. Most were reclassified as either pleomorphic xanthoastrocytoma-like or high-grade glioma-like tumours, and the high-grade glioma-like group had significantly shorter survival (Boisseau et al., 2019).
Low-grade and high-grade features
| Feature | Low-grade appearance | High-grade (anaplastic) appearance |
|---|---|---|
| Cell division | Infrequent | Frequent |
| Dead tissue | Absent | May be present |
| Proliferation index | Low | Higher |
| Behaviour | May still recur | Not always aggressive if fully removed |
Microscopic grade does not always predict how the tumour will behave. Some low-grade tumours with marked swelling around them recur early, while some high-grade tumours that are well defined do better than expected (Janz and Buhl, 2014).
A related tumour: MN1::BEND2 ependymal tumour
Some researchers describe tumours with the MN1::BEND2 fusion as an early ependymal tumour, separate from classical astroblastoma. These occur mostly in young girls and have a very good prognosis with surgery (Lehman, 2023). Classification is still evolving, and your pathologist will explain how your tumour has been labelled.
3. Causes and risk factors
The cause of astroblastoma is unknown.
| Factor | Notes |
|---|---|
| Female sex | Strongly over-represented; female-to-male ratio about 8:1 in one review |
| Young age | Median age about 14 years in a large review |
| MN1 rearrangement | Arises in the tumour only; not inherited |
| X chromosome changes | Frequent losses on the X chromosome in tumour cells (Hirose et al., 2018) |
| Lifestyle or environment | No known link |
| Inherited syndromes | None established |
Why the tumour affects girls and women so much more often is not understood. The involvement of the X chromosome in the gene fusion may be part of the explanation.
4. How does it look
On scans
A systematic review of 127 cases described the typical imaging features (Cunningham et al., 2016).
| Feature | How often reported |
|---|---|
| Above the tentorium (cerebral hemispheres) | 96% |
| Near the surface of the brain | 72% |
| Well-defined borders | 96% |
| Mixed cystic and solid | 93% |
| Contrast enhancement | 99% |
| Calcification on CT | 73% |
| Swelling around the tumour | 80%, usually mild |
| Restricted diffusion on MRI | In all cases where reported |
The solid parts often look dark on both T1 and T2 MRI sequences, and the tumour may have a “bubbly” appearance. Superficial tumours can gradually thin the overlying skull bone.
Under the microscope
| Feature | Description |
|---|---|
| Pseudorosettes | Tumour cells with broad processes arranged around blood vessels |
| Blood vessels | Thickened, glassy (hyalinised) walls |
| Border | Sharp separation from surrounding brain |
| Patterns | Trabecular, pseudopapillary or solid areas |
| Stains | GFAP, Olig2, S-100 and EMA variably positive; IDH1 R132H negative |
Genetic testing
| Test | Purpose |
|---|---|
| MN1 break-apart FISH | Detects MN1 rearrangement |
| RNA sequencing | Identifies the fusion partner, such as BEND2 |
| DNA methylation profiling | Classifies the tumour among related types |
| BRAF and other gene tests | Identify look-alike tumours |
5. Symptoms
Symptoms depend on the size and position of the tumour.
Common symptoms
- Headaches, often worse in the morning
- Seizures, sometimes affecting one part of the body
- Nausea and vomiting
- Dizziness
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Weakness or numbness on one side | Pressure on movement or sensory areas |
| Speech or language difficulties | Tumour in the dominant hemisphere |
| Visual problems | Tumour near visual pathways or raised pressure |
| Behaviour or personality change | Frontal lobe tumours |
| Drowsiness | High pressure in the head |
When to seek urgent help
Seek urgent medical help for a first seizure, a seizure lasting more than five minutes, severe headache with vomiting, sudden weakness or drowsiness.
6. Diagnosis
| Test | Purpose |
|---|---|
| MRI of the brain with contrast | Main imaging test |
| CT scan | Shows calcification and bone changes |
| MRI of the spine | Considered if spread is suspected |
| Surgery or biopsy | Provides tissue for diagnosis |
| Neuropathology with molecular testing | Confirms MN1 alteration and excludes look-alike tumours |
| EEG | If seizures are present |
| Neuropsychology assessment | Baseline memory and thinking skills |
Because tumours with this appearance include several different diseases, experts recommend thorough molecular testing, especially in adults (Boisseau et al., 2019).
7. Treatment
There are no clinical trials specific to this tumour. Treatment is based on case series, reviews and the experience of specialist neuro-oncology teams.
Surgery
| Aspect | Details |
|---|---|
| Aim | Complete (gross total) removal where safe |
| Why it is often possible | The tumour is usually well defined and near the surface |
| Monitoring during surgery | Brain mapping may be used near important areas |
| Repeat surgery | Often used for local recurrence |
Radiotherapy
| Situation | Approach |
|---|---|
| Complete removal of a low-risk tumour | Often observation with MRI scans |
| Incomplete removal | Focal radiotherapy considered |
| Recurrence | Focal radiotherapy, often after further surgery |
| Low-grade tumour with marked swelling | Combined surgery and radiotherapy suggested in one review (Janz and Buhl, 2014) |
In children, teams aim to limit radiotherapy where possible, because of its long-term effects on the developing brain.
Chemotherapy
Chemotherapy has an uncertain role. It is generally reserved for tumours that recur repeatedly or cannot be controlled with surgery and radiotherapy, often within a clinical trial or after specialist review.
Treatment by situation
| Situation | Typical approach |
|---|---|
| MN1-altered, fully removed | MRI surveillance |
| MN1-altered, residual tumour | Further surgery or focal radiotherapy |
| Recurrence | Surgery, radiotherapy, sometimes chemotherapy |
| Astroblastoma-like tumour without MN1 alteration | Treated according to the tumour type found on molecular testing |
Recovery after surgery
| Period | What to expect |
|---|---|
| First days | Close monitoring; headache and tiredness are common |
| 1-2 weeks | Most people go home; wound care and gentle activity |
| 2-4 weeks | Results of molecular tests and a decision about further treatment |
| 1-3 months | Gradual return to school or work, often part-time at first |
| Longer term | Recovery of strength, speech or concentration may continue for months |
Seizure management
| Measure | Details |
|---|---|
| Anti-seizure medicines | Started if seizures occur |
| Review after surgery | Many people can reduce or stop medicines over time |
| Safety advice | Driving, swimming and bathing precautions |
Side effects
| Treatment | Possible side effects |
|---|---|
| Brain surgery | Temporary weakness, speech problems, seizures, infection |
| Radiotherapy | Tiredness, hair loss, memory and learning effects, hormone problems in children |
| Chemotherapy | Low blood counts, nausea, infection risk |
| Anti-seizure medicines | Tiredness, mood changes, dizziness |
8. Outlook (prognosis)
| Factor | Effect |
|---|---|
| MN1 alteration confirmed | Generally associated with a favourable course |
| Complete removal | Better long-term control |
| High-grade glioma-like molecular profile | Much poorer outlook; a different disease |
| Recurrence | Can often be treated again |
In a series of eight astroblastomas, six of the seven patients with follow-up data survived without recurrence, while one had several recurrences (Hirose et al., 2018). Tumours with the MN1::BEND2 fusion in young girls are reported to have a very good prognosis with surgery (Lehman, 2023).
Some tumours recur years later, sometimes as nodules along the brain lining, and may show more aggressive features over time (Janz and Buhl, 2014).
9. Follow-up
| Time | Typical checks |
|---|---|
| After surgery | MRI within days to confirm the extent of removal |
| First 2 years | MRI every 3-6 months |
| Years 3-5 | MRI every 6-12 months |
| After 5 years | Yearly or less often, as advised |
| Children | Growth, hormone, learning and school support |
10. Living with astroblastoma
- Take anti-seizure medicines as prescribed and keep a seizure diary
- Follow driving rules after seizures or brain surgery
- Ask for school or workplace adjustments during recovery
- Rest and pace activities; fatigue is common
- Ask about neuropsychology support for memory or concentration
- Keep follow-up scans, even after years without problems
- Tell teachers and employers about seizure first aid if seizures are a risk
- Seek support from brain tumour and children’s cancer charities
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is astroblastoma cancer? | It is a primary brain tumour; its behaviour ranges from slow-growing to more aggressive |
| Why is the MN1 test important? | It confirms the diagnosis and separates it from look-alike tumours with different outlooks |
| Why does it affect girls more? | The reason is unknown; X chromosome changes may be involved |
| Is it inherited? | No; brothers and sisters do not need screening |
| How long will recovery take? | Often weeks to a few months, depending on the tumour’s position |
| Will I need radiotherapy? | Not always; often only if removal is incomplete or the tumour recurs |
| Can it come back? | Yes, sometimes years later, so scans continue long term |
| Can I play sport after treatment? | Usually, once your team agrees; contact sports may need a longer wait |
| Will it affect fertility? | Surgery does not; ask your team about possible effects of radiotherapy or chemotherapy |
| Can I live a normal life? | Many people return to school, work and usual activities |
12. Questions to ask your care team
- Has an MN1 alteration been confirmed, and what is the partner gene?
- Was the tumour completely removed?
- Do I need radiotherapy now, or only if it returns?
- How will we manage seizures?
- How often will I have MRI scans?
- What support is available for school, work and memory?
- Should my samples be reviewed at a reference centre for rare brain tumours?
- Is there a registry or study collecting information on this tumour?
Resources
- Boisseau, W. et al. (2019) ‘Molecular profiling reclassifies adult astroblastoma into known and clinically distinct tumor entities with frequent mitogen-activated protein kinase pathway alterations’, The Oncologist, 24(12), pp. 1584-1592.
- Cunningham, D.A. et al. (2016) ‘Neuroradiologic characteristics of astroblastoma and systematic review of the literature: 2 new cases and 125 cases reported in 59 publications’, Pediatric Radiology, 46(9), pp. 1301-1308.
- Hirose, T. et al. (2018) ‘Astroblastoma: a distinct tumor entity characterized by alterations of the X chromosome and MN1 rearrangement’, Brain Pathology, 28(5), pp. 684-694.
- Janz, C. and Buhl, R. (2014) ‘Astroblastoma: report of two cases with unexpected clinical behavior and review of the literature’, Clinical Neurology and Neurosurgery, 125, pp. 114-124.
- Lehman, N.L. (2023) ‘Early ependymal tumor with MN1-BEND2 fusion: a mostly cerebral tumor of female children with a good prognosis that is distinct from classical astroblastoma’, Journal of Neuro-Oncology, 161(3), pp. 425-439.
- National Cancer Institute (2026) Adult Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.